Momenta Pharmaceuticals Initiates Phase I Clinical Study for M118 Subcutaneous Formulation

Momenta Pharmaceuticals, Inc. has initiated a Phase I study of a subcutaneous formulation of M118, its lead novel development candidate.

The study will evaluate the human safety, tolerability, bioavailability and pharmacokinetics of the compound.

M118 is a next-generation anticoagulant designed specifically for use in treating patients diagnosed with acute coronary syndromes (ACS).

M118 administered intravenously demonstrates superior efficacy to a standard dose of unfractionated heparin (UFH) in a preclinical model of acute arterial thrombosis.

This increase in efficacy did not result in an increased risk of bleeding.

It is anticipated that an important feature of M118 will be its flexibility in being formulated for both intravenous and subcutaneous administration to be most appropriate for individual ACS patients.

Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc.


DownloadFull Press Release

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera